

A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)

NCT05562947

Status	RECRUITING
Phase	Phase 3
Sponsor	Hoffmann-La Roche
Enrollment	68 participants

Key Eligibility Criteria

Inclusion (7)

- Initial diagnosis of nAMD within 9 months prior to the screening visit
 - Previous treatment with at least three anti-vascular endothelial growth factor (VEGF) IVT injections for nAMD per standard of care within 6 months prior to the screening visit
 - Demonstrated response to prior anti-VEGF IVT treatment since diagnosis
 - Availability of historical VA data prior to the first anti-VEGF treatment for nAMD up to the screening visit
 - BCVA of 34 letters or better (20/200 or better approximate Snellen equivalent), using Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters
- ... and 2 more (see full listing online)

Exclusion (38)

- A. Prior Ocular Treatment Study Eye
 - History of vitrectomy surgery, submacular surgery, or other surgical intervention, all for AMD
 - Prior treatment with Visudyne, external-beam radiation therapy, or transpupillary thermotherapy
 - Previous treatment with corticosteroid IVT injection
 - Previous intraocular device implantation (not including intraocular lens implants)
- ... and 33 more (see full listing online)

Locations (16 total)

Peking Union Medical College Hospital, Beijing, China
Beijing Hospital, Beijing, China
Beijing Tongren Hospital, Beijing, China
... and 13 more locations